Breast cancer patients with hormone receptor-positive (HR+) tumors have better clinical outcomes after receiving endocrine therapy than those with HR-negative (HR-) tumors; however, nearly half of ER-positive (ER+) breast cancers do not respond to or develop resistance to hormonal therapy [7–9]. This evidence concerns the gene ESR1 and breast cancer.